# A Study of EPEG in Beta Thalassemia Patients

> **NCT02950857** · PHASE1 · COMPLETED · sponsor: **Prolong Pharmaceuticals** · enrollment: 6 (actual)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **DRUG:** EPEG

## Key facts

- **NCT ID:** NCT02950857
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-28
- **Primary completion:** 2017-09-27
- **Final completion:** 2017-09-27
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2018-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02950857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02950857, "A Study of EPEG in Beta Thalassemia Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02950857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*